Medindia

X

Varian Medical Systems Ranked No. 1 in 2008 KLAS Report on Oncology IT Vendors

Tuesday, July 8, 2008 General News J E 4
Advertisement
PALO ALTO, Calif., July 8 Varian Medical Systems(NYSE: VAR) ranked #1 in an independent study released last week by KLAS, aresearch firm that specializes in monitoring and reporting on the performanceof healthcare vendors. Varian's ARIA(TM) software, a comprehensiveinformation system for managing medical and radiation oncology practices,received top scores in study categories including: ease of use, quality ofreleases and updates, and compatibility with third party products.

According to the June 2008 Oncology report, Varian Medical Systems is"considered by many providers to have the most developed and comprehensiveoncology solution." The report further states that "many Varian customersfeel that the ARIA suite is the most robust solution for medical and radiationoncology available on the market today."

Although KLAS interviewed eleven potential vendors, the study focuses onVarian, IMPAC, and IntrinsiQ, the only three with a sufficient number ofactive installations to qualify.

Varian was the only vendor to score above the group average in all four ofthe report's major categories: product/technology indicators, serviceindicators, success indicators, and business indicators. Varian scored abovecompetitors in 23 of the forty indicators that the study measured, whileIntrinsiQ scored highest in 13, and IMPAC in six. Some of the indicators forwhich Varian achieved top scores included: ease of use; quality of releases orupdates; technology that is easy to implement and support; works withthird-party producers; quality of implementation, training, and documentation;quality and timeliness of interfaces; helps your job performance, and overallsatisfaction with vendor/product.

All of the CIOs, managers, doctors, nurses, IT directors, and otheradministrators and healthcare professionals surveyed about their experiencewith Varian's oncology information system said that they:

The KLAS study predicts that Varian will continue to be seen as one of themost complete medical and radiation oncology solutions for some time to come.

"We're gratified to receive top marks in an objective survey of ourcustomers," said Dow Wilson, president of the company's Oncology Systemsbusiness. "It validates the work we're doing to offer treatment centers aversatile set of best-in-class clinical tools for fighting cancer."

ABOUT VARIAN MEDICAL SYSTEMS

Varian Medical Systems, Inc., of Palo Alto, California, is the world'sleading manufacturer of medical devices and software for treating cancer andother medical conditions with radiotherapy, radiosurgery, proton therapy, andbrachytherapy. The company supplies informatics software for managingcomprehensive cancer clinics, radiotherapy centers and medical oncologypractices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and alsosupplies X-ray imaging products for cargo screening and industrial inspection.Varian Medical Systems employs approximately 4,600 people who are located atmanufacturing sites in North America and Europe and in its 60 sales andsupport offices around the world. For more information, visithttp://www.varian.com/.

ABOUT KLAS

KLAS is a research firm specializing in monitoring and reporting theperformance of healthcare vendors. KLAS' mission is to improve delivery, byindependently measuring vendor performance for the benefit of our healthcareprovider partners, consultants, investors, and vendors. Working together withexecutives from over 4500 hospitals and over 2500 clinics, KLAS deliverstimely reports, trends, and statistics, which provide a solid overview ofvendor performance in the industry. KLAS measures performance of software,professional services, and medical equipment vendors. For more information, goto http://www.KLASresearch.com, email marketing@KLASresearch.com,
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Telik Announces Publication of Diabetes Research i...
S
The Health Information Trust Alliance (HITRUST) Se...